Clorox (CLX) Misses Q4 EPS by 41c, Guidance Falls Short of Consensus

Clorox (NYSE: CLX) reported Q4 EPS of $0.95, $0.41 worse than the analyst estimate of $1.36. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.92 billion.

GUIDANCE:

Clorox sees FY2022 EPS of $5.40-$5.70, versus the consensus of $7.61.

• 2% to 6% decrease in sales (2% to 6% decrease in organic sales)
• $5.05 to $5.35 diluted EPS range (9% to 4% decrease versus year ago)
• $5.40 to $5.70 adjusted EPS range (26% to 21% decrease versus year ago)Excludes the strategic investment in digital capabilities and productivity enhancements detailed below.
• Gross margin down by 300 to 400 basis points

For earnings history and earnings-related data on Clorox (CLX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• L3Harris CEO steps down amid conduct review, shares drop